Warning: The NCBI web site requires JavaScript to function. more...
Indiana University Simon Cancer Center, Indianapolis, IN 46220, USA. bpschnei@iupui.edu
Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on